Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Using Quantra bedside clot testing to guide blood transfusions during liver transplant

Official title: Assessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation

Run by University Hospital, Toulouse · NCT06749405 · Data updated 2026-11-12

This will test whether using Quantra bedside clot testing during liver transplants can reduce bleeding and the need for blood transfusions in adults with end-stage liver disease.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment56 (estimated)
SponsorUniversity Hospital, Toulouse
Academic / other
Locations1 site (Toulouse)
StatusRecruiting
StartedMarch 8, 2025
Main results expectedMarch 2027
Study endsMarch 2027
Registry record updatedSeptember 22, 2025
Trial IDNCT06749405 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with end-stage liver disease scheduled for liver transplantation who can provide informed consent and are not listed for multi-organ transplant are ideal candidates.

Probably not a fit

Patients undergoing multi-organ transplantation, those with congenital bleeding disorders, pregnant or breastfeeding women, or people under legal protection are excluded and unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares a transfusion algorithm guided by the Quantra bedside viscoelastic sonorheometry device with a conventional transfusion approach in adults undergoing orthotopic liver transplantation. Participants receive intraoperative haemostatic management according to one of the two predefined algorithms, and transfusion volumes and bleeding-related outcomes are recorded. The trial focuses on real-time guidance of blood-product administration during the perioperative period to respond to dynamic coagulation changes common in end-stage liver disease. Primary outcomes include transfusion requirements and measures of intraoperative bleeding, with safety monitored throughout.

Why it matters

Potential benefit: If successful, the Quantra-guided approach could reduce blood transfusions and bleeding during liver transplantation, potentially lowering complications and resource use.

How similar studies have gone: Viscoelastic-guided transfusion strategies using TEG or ROTEM have shown benefit in some surgical settings, but Quantra's sonorheometric approach is newer and less extensively validated in liver transplantation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged 18 years or older
* Patient with ESLD undergoing liver transplantation
* Individuals affiliated with or beneficiaries of a social security scheme
* Free and informed written consent obtained in writing from the patient, or where applicable from the trusted person/family member/close relative

Non-inclusion Criteria:

* Multi-organ transplantation
* Congenital haemostasis disorder (such as haemophilia)
* Patient under juridical protection (persons deprived of liberty or under curatorship or guardianship or safeguard of justice)
* Pregnant or breast-feeding woman
* Patient already enrolled in another interventional study with primary or secondary objective of reducing perioperative bleeding or transfusion

Where it's running

  • Toulouse University Hospital
    Toulouse, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.